Fosnetupitant
Akynzeo (fosnetupitant) is a small molecule pharmaceutical. Fosnetupitant was first approved as Akynzeo on 2018-04-19.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Akynzeo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosnetupitant chloride hydrochloride
+
Palonosetron hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AKYNZEO | Helsinn Healthcare | N-210493 RX | 2018-04-19 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| akynzeo | New Drug Application | 2020-10-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FOSNETUPITANT CHLORIDE HYDROCHLORIDE / PALONOSETRON HYDROCHLORIDE, AKYNZEO, HELSINN HLTHCARE | |||
| 2023-04-19 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fosnetupitant Chloride Hydrochloride / Palonosetron Hydrochloride, Akynzeo, Helsinn Hlthcare | |||
| 10624911 | 2037-06-02 | DP | |
| 11529362 | 2037-06-02 | DP | |
| 8426450 | 2032-05-23 | DS, DP | |
| 8895586 | 2032-05-23 | U-2301 | |
| 9403772 | 2032-05-23 | DP | U-2301 |
| 9908907 | 2032-05-23 | DS, DP | |
| 10208073 | 2032-05-23 | U-2301 | |
| 10717721 | 2032-05-23 | DP | |
| 11312698 | 2032-05-23 | DS, DP | |
| 10828297 | 2030-12-17 | U-2301 | |
| 9186357 | 2030-11-18 | U-2301 | |
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | 1 | 2 | |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 2 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | — | — | — | 1 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 4 | 4 | ||
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
| Essential hypertension | D000075222 | I10 | — | — | — | — | 1 | 1 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FOSNETUPITANT |
| INN | fosnetupitant |
| Description | Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant. It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1703748-89-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989917 |
| ChEBI ID | — |
| PubChem CID | 71544786 |
| DrugBank | DB14019 |
| UNII ID | T672P80L2S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 71 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,117 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more